Ildong Pharmaceutical financials at a glance
| Year | Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
₩483.23B | ₩460.65B | ₩503.91B | ₩517.47B | ₩561.85B | ₩560.13B | ₩637.71B | ₩600.76B | ₩0.00M |
| GM % | Gross Margin % |
|
48.26% | 49.07% | 50.59% | 44.85% | 42.39% | 39.13% | 37.03% | 35.56% | 0.00% |
| OM | Operating Margin |
|
7.35% | 5.51% | 5.39% | -0.30% | 0.98% | -9.71% | -11.55% | -8.89% | 0.00% |
| EPS | Earnings Per Share |
|
₩896.15 | ₩534.29 | ₩-598.00 | ₩-5363.00 | ₩-3338.00 | ₩0.00 | |||
| Div. | Dividends |
|
₩0.00 | ₩362.81 | ₩380.95 | ₩380.95 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| PR % | Payout Ratio % |
|
0 | 40.49% | 71.30% | -63.70% | 0 | 0 | 0 | 0 | 0 |
| Sha. | Shares |
|
23.81m | 23.81m | 23.8m | 23.79m | 23.79m | 23.79m | 26.79m | 0m | 27.93m |
| OCF | Operating Cash Flow |
|
₩45.98B | ₩73.72B | ₩66.65B | ₩41.37B | ₩19.37B | ₩-11365.96M | ₩-53540.65M | ₩-36615.40M | ₩0.00M |
| FCF | Free Cash Flow |
|
₩26.12B | ₩55.93B | ₩50.67B | ₩28.37B | ₩5.01B | ₩-25991.59M | ₩-54000.00M | ₩-101000.00M | ₩0.00M |
| FCFS | Free Cash Flow Per Share |
|
₩565.42 | ₩1.31k | ₩1.94k | ₩1.01k | ₩102.66 | ₩-1297.74 | ₩-2726.05 | ₩-1915.83 | ₩0.00 |